Molecular Characterization of Induced Neuronal Cells in Parkinson's Disease
Primary Purpose
Parkinson Disease
Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Skin biopsy
Sponsored by
About this trial
This is an interventional other trial for Parkinson Disease
Eligibility Criteria
Inclusion Criteria: Subjects aged 18 years or older Patients with Parkinson's disease, according to the most recent diagnostic criteria Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study Exclusion Criteria: Patients affected by drug-induced parkinsonism or atypical parkinsonian disorders Patients with neurological diseases other than Parkinson's disease Inability to sign an informed consent Severe psychiatric diseases
Sites / Locations
- Flavia TorlizziRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Skin biopsy
Arm Description
Outcomes
Primary Outcome Measures
Neurophysiological characterization of dopaminergic neurons derived from patients with Parkinson's disease.
To evaluate the firing frequency in the dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.
Biochemical characterization of dopaminergic neurons derived from patients with Parkinson's disease.
To determine the amount of dopamine released from differentiated neurons derived from fibroblasts of patients with Parkinson's disease.
α-synuclein misfolding in dopaminergic neurons derived from patients with Parkinson's disease.
To document the presence of abnormal accumulation of misfolded alpha-synuclein in the dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.
Secondary Outcome Measures
Full Information
NCT ID
NCT05797779
First Posted
February 28, 2023
Last Updated
March 21, 2023
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
1. Study Identification
Unique Protocol Identification Number
NCT05797779
Brief Title
Molecular Characterization of Induced Neuronal Cells in Parkinson's Disease
Official Title
Molecular Characterization of Induced Neuronal Cells Derived From Fibroblasts of Patients With Parkinson's Disease
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 25, 2021 (Actual)
Primary Completion Date
June 1, 2024 (Anticipated)
Study Completion Date
March 25, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
To describe the molecular, electrophysiological and morphological expression profile of dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
45 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Skin biopsy
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Skin biopsy
Intervention Description
Punch biopsy of the skin
Primary Outcome Measure Information:
Title
Neurophysiological characterization of dopaminergic neurons derived from patients with Parkinson's disease.
Description
To evaluate the firing frequency in the dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.
Time Frame
Baseline
Title
Biochemical characterization of dopaminergic neurons derived from patients with Parkinson's disease.
Description
To determine the amount of dopamine released from differentiated neurons derived from fibroblasts of patients with Parkinson's disease.
Time Frame
Baseline
Title
α-synuclein misfolding in dopaminergic neurons derived from patients with Parkinson's disease.
Description
To document the presence of abnormal accumulation of misfolded alpha-synuclein in the dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.
Time Frame
Baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects aged 18 years or older
Patients with Parkinson's disease, according to the most recent diagnostic criteria
Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study
Exclusion Criteria:
Patients affected by drug-induced parkinsonism or atypical parkinsonian disorders
Patients with neurological diseases other than Parkinson's disease
Inability to sign an informed consent
Severe psychiatric diseases
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Guido Alessandro Primiano, MD
Phone
+390630156433
Email
guidoalessandro.primiano@policlinicogemelli.it
First Name & Middle Initial & Last Name or Official Title & Degree
Flavia Torlizzi
Phone
0630156433
Email
flavia.torlizzi@policlinicogemelli.it
Facility Information:
Facility Name
Flavia Torlizzi
City
Roma
ZIP/Postal Code
00168
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Flavia Torlizzi
Phone
+390630156433
Email
flavia.torlizzi@policlinicogemelli.it
12. IPD Sharing Statement
Learn more about this trial
Molecular Characterization of Induced Neuronal Cells in Parkinson's Disease
We'll reach out to this number within 24 hrs